November 23, 2021
The Honorable Chiquita Brooks-LaSure
Administrator
Centers for Medicare and Medicaid Services
Department of Health and Human Services
7500 Security Boulevard
Baltimore, MD 21244-1850
Via Electronic Delivery Re: Step Therapy for Part B Drugs in Medicare Advantage
Dear Administrator Brooks-LaSure,
The undersigned organizations, representing millions of Medicare beneficiaries with life-threatening, complex, chronic conditions and/or the physicians who care for them, are asking the Centers for Medicare and Medicaid Services (CMS) to ensure that beneficiaries enrolled in Medicare Advantage plans continue to have appropriate and timely access to the therapies they need to properly manage their conditions. CMS was recently presented with current examples of patient harm due to the implementation of utilization management protocols and we are asking that the agency move swiftly to reinstate the step therapy prohibition in Medicare Advantage (MA) plans for Part B drugs.
More Advocacy Letters
Advocacy Letter
MGMA Joins Letter on DEA Telehealth Extension (July 22, 2025)
Advocacy Letter
MGMA responds to CMS’ RFI on deregulation (June 10, 2025)
